Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
As regards to the FokI polymorphism, the FF genotype was associated with lower levels of the pro-inflammatory cytokine IL-1β (p = 0.045).Distribution of clinical variables according to the VDR genotypes.BsmI A > G (rs1544410)bbBbBBOverallp-value N (%) CP stage 0.044 A12 (45.8)32 (60.4)2 (22.2)46 (51.3)B11 (41.7)13 (23.3)2 (22.2)26 (28.9)C3 (12.5)9 (16.3)5 (55.6)17 (19.8) Median (IQR) Vitamin D levels (ng/mL)20.6 (14.8, 29.6)21.5 (14.7, 31.6)29.8 (11.2, 46.7)21.1 (14.7, 31.6)0.828MELD12.0 (8.5, 17.0)10.0 (8.0, 14.0)16.0 (12.0, 19.0)11.0 (8.0, 15.5) 0.045 VDBP (μg/mL)177.6 (143.9, 259.0)136.4 (89.7, 256.7)199.3 (126.8, 209.6)160.8 (99.3, 257.9)0.307IL-12 (pg/mL)6.9 (0.0, 8.7)8.0 (5.6, 8.7)5.9 (0.0, 6.8)7.5 (2.1, 8.7)0.438TNF-a (pg/mL)4.9 (1.0, 5.9)4.6 (1.5, 5.3)5.2 (0.3, 6.0)4.7 (1.2, 5.7)0.764IL-1β (pg/mL)8.1 (6.5, 12.6)7.9 (6.2, 11.5)7.5 (0.0, 11.2)8.0 (3.1, 11.6)0.752IL-6 (pg/mL)5.8 (5.1, 12.8)7.8 (4.3, 27.2)13.0 (6.5, 49.4)7.8 (4.3, 22.0)0.520IL-8 (pg/mL)33.5 (16.0, 101.6)41.3 (23.0, 87.9)29.3 (20.9, 44.3)35.7 (20.6, 90.7)0.698IL-10 (pg/mL)3.7 (2.0, 4.2)4.0 (3.3, 5.2)4.0 (3.7, 6.3)3.9 (3.1, 4.7)0.257LBP (μg/mL)9.8 (4.9, 11.3)10.8 (8.4, 11.6)11.3 (11, 11.4)10.8 (8.3, 11.4)0.128FokI C > T (rs10735810) ff Ff FF Overall p: value N (%) CP stage0.846A4 (42.8)21 (53)21 (51.4)46 (51.3)B4 (42.8)9 (23.5)13 (31.4)26 (28.9)C1 (14.2)9 (23.5)7 (17.2)17 (19.8) Median (IQR) Vitamin D levels (ng/mL)30.3 (21.3, 46.7)22.0 (14.7, 32.2)18.4 (13.9, 26.4)21.1 (14.7, 31.6)0.139MELD12.0 (9.0, 13.0)11.0 (8.0, 16.0)11.0 (8.0, 17.0)11.0 (8.0, 15.5)0.983VDBP (μg/mL)217.8 (189.0, 282.9)147.3 (112.2, 270.4)159.3 (89.7, 220.8)160.8 (99.3, 257.9)0.355IL-12 (pg/mL)5.3 (0.0, 8.2)7.5 (5.3, 8.9)8.0 (0.0, 8.5)7.5 (2.1, 8.7)0.382TNF-a (pg/mL)4.9 (1.6, 5.8)4.6 (1.5, 5.7)4.7 (0.4, 5.7)4.7 (1.2, 5.7)0.846IL-1β (pg/mL)9.3 (7.5, 11.8)9.4 (7.4, 12.3)7.2 (0.0, 10.1)8.0 (3.1, 11.6) 0.045 IL-6 (pg/mL)5.8 (5.1, 7.7)7.8 (4.2, 20.1)9.8 (4.9, 29.4)7.8 (4.3, 22.0)0.712IL-8 (pg/mL)33.7 (20.8, 87.9)44.7 (22.6, 110.4)33.0 (20.4, 85.8)35.7 (20.6, 90.7)0.812IL-10 (pg/mL)3.7 (1.8, 4.7)3.8 (3.2, 4.6)4.0 (3.2, 4.6)3.9 (3.1, 4.7)0.970LBP (μg/mL)10.8 (9.6, 11.3)10.5 (8.7, 11.3)10.9 (4.3, 11.4)10.8 (8.3, 11.4)0.995ApaI G > T (rs7975232) aa Aa AA Overall p: value N (%) CP stage 0.001 A3 (30)29 (63.4)13 (40)45 (51.3)B7 (60)14 (29.3)5 (16)26 (28.9)C1 (10)3 (7.3)14 (44)18 (19.8) Median (IQR) Vitamin D levels (ng/mL)20.0 (9.5, 26.2)20.8 (14.9, 30.4)24.1 (14.1, 33.6)21.1 (14.7, 31.6)0.754Diastolic pressure (mmHg)60.0 (60.0, 70.0)77.5 (70.0, 90.0)77.5 (70.0, 80.0)75.0 (70.0, 80.0) 0.011 MELD9.5 (8.0, 14.0)11.0 (8.0, 14.0)13.0 (9.0, 17.0)11.0 (8.0, 15.5)0.377VDBP (μg/mL)244.9 (157.6, 288.6)170.8 (101.1, 256.7)130.2 (81.7, 215.3)160.8 (99.3, 257.9)0.140IL-12 (pg/mL)8.5 (5.1, 9.0)7.7 (0.0, 8.5)7.0 (4.7, 8.5)7.5 (2.1, 8.7)0.794TNF-a (pg/mL)5.6 (1.0, 5.9)4.4 (1.5, 5.2)5.0 (1.1, 6.1)4.7 (1.2, 5.7)0.394IL-1β (pg/mL)8.1 (0.0, 12.6)7.3 (0.0, 9.6)10.1 (7.5, 11.7)8.0 (3.1, 11.6)0.076IL-6 (pg/mL)7.7 (5.5, 12.3)5.8 (4.1, 17.6)12.9 (5.2, 29.8)7.8 (4.3, 22.0)0.177IL-8 (pg/mL)33.7 (19.9, 146.9)27.9 (19.5, 83.5)45.5 (24.4, 200.2)35.7 (20.6, 90.7)0.076IL-10 (pg/mL)3.7 (0.8, 4.0)3.9 (3.1, 4.6)4.1 (3.4, 5.4)3.9 (3.1, 4.7)0.297LBP (μg/mL)9.4 (3.8, 11.3)10.2 (4.6, 11.3)11.3 (10.5, 11.4)10.8 (8.3, 11.4) 0.014 TaqI C > T (rs731236) tt Tt TT Overall p: value N (%) CP stage 0.027 A12 (42.3)33 (63.4)2 (22.2)47 (51.3)B12 (42.3)11 (22)2 (22.2)25 (28.9)C4 (15.4)8 (14.6)5 (55.6)17 (19.8) Median (IQR) Vitamin D levels (ng/mL)21.2 (15.5, 30.8)20.8 (14.7, 30.3)29.8 (11.2, 46.7)21.1 (14.7, 31.6)0.719MELD12.0 (9.0, 17.0)10.0 (8.0, 14.0)16.0 (12.0, 19.0)11.0 (8.0, 15.5) 0.025 VDBP (μg/mL)175.8 (123.8, 259.0)140.5 (90.9, 259.3)199.3 (126.8, 209.6)160.8 (99.3, 257.9)0.597IL-12 (pg/mL)8.0 (0.0, 9.0)7.8 (5.4, 8.6)5.9 (0.0, 6.8)7.5 (2.1, 8.7)0.475TNF-a (pg/mL)5.2 (1.0, 5.9)4.5 (1.5, 5.3)5.2 (0.3, 6.0)4.7 (1.2, 5.7)0.595IL-1β (pg/mL)8.1 (6.5, 12.6)7.9 (3.1, 11.6)7.5 (0.0, 11.2)8.0 (3.1, 11.6)0.786IL-6 (pg/mL)7.7 (5.1, 13.8)7.6 (4.3, 23.6)13.0 (6.5, 49.4)7.8 (4.3, 22.0)0.569IL-8 (pg/mL)33.7 (16.0, 101.6)41.3 (22.9, 90.7)29.3 (20.9, 44.3)35.7 (20.6, 90.7)0.759IL-10 (pg/mL)3.8 (2.0, 4.4)3.9 (3.3, 5.0)4.0 (3.7, 6.3)3.9 (3.1, 4.7)0.468LBP (μg/mL)10.2 (5.2, 11.3)10.7 (8.2, 11.4)11.3 (11.0, 11.4)10.8 (8.3, 11.4)0.200Abbreviations: IQR, Interquartile range; CP, Child Pugh; MELD, Model for end-stage liver disease; VDBP, Vitamin D binding protein; LBP, Lipopolysaccharide binding protein.
Source: Distribution of clinical variables and serum cytokine expression according to the VDR genotypes. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This study was a prospective cohort study, on 89 consecutive Caucasian patients with liver cirrhosis.
Source: Methods.
During the recruitment, all cirrhotic patients were in stable clinical condition, without any severe complication of liver disease including gastro-intestinal bleeding, hepatorenal syndrome, moderate to severe hepatic encephalopathy, spontaneous bacterial peritonitis, malignancy, or organ failure.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis
Cohort study · Scientific Reports · 2018
Original publication title
Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis
© The Author(s) 2018
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Several polymorphisms in the vitamin D receptor (VDR) are associated with the occurrence of chronic liver disease. Here, we investigated the association between BsmI, ApaI, TaqI and FokI VDR polymorphisms and the severity of liver cirrhosis in relation to serum cytokine and lipopolysaccharide binding protein (LBP) levels and their role on survival in cirrhotic patients. We found that patients harboring the BB genotype had higher MELD score, and they were mainly at CP stage C; patients harboring the AA genotype had increased LBP, IL-1β and IL-8 levels, and they were mostly at CP stage C; TT genotype carriers had higher MELD score and they were mainly at CP stage C and FF genotype carriers had lower IL-1β levels when compared to Bb/bb, Aa/aa, Tt/tt and Ff/ff genotypes respectively.
In the multivariate analysis ApaI, BsmI and TaqI polymorphisms were independently associated with liver cirrhosis severity. In the survival analysis, the independent prognostic factors were CP score, MELD and the FF genotype. Our results indicate that the ApaI, TaqI and BsmI polymorphisms are associated with the severity of liver cirrhosis, through the immunoregulatory process. Survival is related to the FF genotype of FokI polymorphism, imparting a possible protective role in liver cirrhosis.
Authors’ abstract
Several polymorphisms in the vitamin D receptor (VDR) are associated with the occurrence of chronic liver disease. Here, we investigated the association between BsmI, ApaI, TaqI and FokI VDR polymorphisms and the severity of liver cirrhosis in relation to serum cytokine and lipopolysaccharide binding protein (LBP) levels and their role on survival in cirrhotic patients. We found that patients harboring the BB genotype had higher MELD score, and they were mainly at CP stage C; patients harboring the AA genotype had increased LBP, IL-1β and IL-8 levels, and they were mostly at CP stage C; TT genotype carriers had higher MELD score and they were mainly at CP stage C and FF genotype carriers had lower IL-1β levels when compared to Bb/bb, Aa/aa, Tt/tt and Ff/ff genotypes respectively.
In the multivariate analysis ApaI, BsmI and TaqI polymorphisms were independently associated with liver cirrhosis severity. In the survival analysis, the independent prognostic factors were CP score, MELD and the FF genotype. Our results indicate that the ApaI, TaqI and BsmI polymorphisms are associated with the severity of liver cirrhosis, through the immunoregulatory process. Survival is related to the FF genotype of FokI polymorphism, imparting a possible protective role in liver cirrhosis.
Publication and source details
Original title: Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis
Christos Triantos; Ioanna Aggeletopoulou; Maria Kalafateli; Panagiota I. Spantidea; Georgia Vourli; Georgia Diamantopoulou; Dimitra Tapratzi; Marina Michalaki; Spilios Manolakopoulos; Charalambos Gogos; Venetsana Kyriazopoulou; Athanasia Mouzaki; Konstantinos Thomopoulos
Scientific Reports · 2018
© The Author(s) 2018https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Hellenic Association for the Study of the LiverRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T04:25:57.714035+00:00
DOI: 10.1038/s41598-018-32482-3 · PMC6138740